HIV in a 28-Year-Old Truck Driver: A Complete 15-Mark Answer

Truck drivers are classified as a bridge population in India's HIV epidemic - they act as a link between high-risk groups (FSWs, IDUs) and the general population. Park's text notes dedicated sentinel surveillance sites for truckers under NACP.

I. MODES OF TRANSMISSION OF HIV

A. Sexual Transmission (Most common globally and in India)

• Unprotected vaginal, anal, or orogenital intercourse
• Anal intercourse carries the highest per-act risk (receptive > insertive)
• Heterosexual transmission is the dominant route in India and Asia
• Risk is amplified by concurrent STIs (breach of mucosal barrier), high viral load, and lack of male circumcision
• Truck drivers are at high risk due to contact with female sex workers (FSWs) at truck stops

B. Blood and Blood Product Transmission

• Sharing of contaminated needles/syringes by intravenous drug users (IDUs) - HIV can remain infectious in a used needle for up to 6 weeks
• Transfusion of unscreened blood or blood products (now negligible with routine screening since 1985)
• Needle-stick injuries and mucous membrane exposure to infected blood (occupational hazard for healthcare workers)
• Sharing of razors, tattoo needles, and unsterilized instruments

C. Mother-to-Child Transmission (MTCT) / Vertical Transmission

• In utero (transplacental): ~20-30% of vertical transmission
• Intrapartum (during labor and delivery): ~50-60% of vertical transmission - most common
• Postpartum (breastfeeding): ~14% additional risk
• Without intervention, overall MTCT risk is ~25% in non-breastfeeding and up to 45% with prolonged breastfeeding
• Maternal viral load is the single most important determinant of MTCT risk

D. Routes NOT implicated

• Casual contact, handshaking, sharing utensils, coughing, sneezing, mosquito bites, water, or food

II. ICTC (INTEGRATED COUNSELLING AND TESTING CENTRE) SERVICES

A. Types of ICTCs (Park's Textbook, p. 491-492)

B. Core Counselling Services at ICTC

• Establish rapport and maintain confidentiality
• Obtain informed written consent before testing
• Assess risk behaviour (sexual history, injecting drug use, transfusion history)
• Provide information on HIV/AIDS, modes of transmission, and prevention
• Explain the meaning of HIV test results (positive, negative, window period)
• Discuss the 3-6 week window period; advise repeat testing if exposure was recent
• Address fears, myths, and stigma
• Psychological preparation for a possible positive result

• Performed on same serum/plasma sample
• Test 1 (highest sensitivity): If non-reactive → Negative; If reactive → proceed to Test 2
• Test 2 (different antigen/principle): If reactive → proceed to Test 3
• Test 3 (tie-breaker): If reactive → HIV confirmed positive
• Detects both HIV-1 and HIV-2 antibodies (and p24 antigen in 4th generation tests)

• Disclosure of result in private, supportive setting
• Immediate emotional support and crisis counselling
• Disclosure counselling - encouraging partner notification
• Information on CD4 count, viral load, and ART eligibility
• Linkage to ART centre for treatment
• Prevention counselling: condom use, avoiding needle sharing, not donating blood
• Psychosocial support and referral to PLHIV networks/support groups
• Nutritional counselling and positive living education
• Referral for partner and index testing

• Explain that negative result may represent window period
• Advise on safer sexual practices (consistent condom use)
• Advise on PrEP eligibility for high-risk individuals
• Re-testing schedule if recent exposure
• Behaviour change communication (BCC)

• Newly diagnosed PLHIV are counselled to share details of sexual and needle-sharing contacts and biological children below 19 years
• Contacts are motivated to avail HIV counselling and testing services
• This provider-assisted referral approach maximises case detection in high-risk networks

• Adherence counselling for ART
• STI/RTI management counselling
• Condom promotion and provision
• Partner tracing and notification
• Referral for OI management, TB-HIV co-management
• Documentation and reporting

III. NACP (NATIONAL AIDS CONTROL PROGRAMME) GUIDELINES

A. Evolution of NACP

B. "Test and Treat" Policy

• Government of India adopted Universal Test and Treat (UTT) in 2017
• All HIV-positive individuals are eligible for ART regardless of CD4 count or clinical stage
• This is aligned with WHO 2016 recommendations

C. First-Line ART Regimen (National Guidelines 2021)

• Preferred first-line regimen: TDF + 3TC + DTG (Tenofovir + Lamivudine + Dolutegravir)
• Free of cost through ART centres (>700 ART centres nationwide)
• CD4 count and viral load testing provided free

D. 95-95-95 Targets (by 2025)

1. 95% of all PLHIV know their HIV status
2. 95% of diagnosed PLHIV receive ART
3. 95% of those on ART achieve viral suppression

E. Key Prevention Strategies under NACP

• Targeted Interventions (TI): For high-risk groups - FSWs, MSM, IDUs, truckers, migrants
• Link Worker Scheme: For bridge populations in rural areas
• Condom promotion and provision: Through ICTC, ART, STI, TI facilities; social marketing
• Blood safety: Mandatory screening of all blood donations
• Needle Syringe Programme (NSP) / Opioid Substitution Therapy (OST): For IDUs
• IEC/BCC: Information, Education, Communication for behaviour change
• HIV-TB collaborative activities: Isoniazid Preventive Therapy (IPT) for PLHIV; TB screening at ART centres
• Condom Vending Machines: At truck stops, highway dhabas - especially relevant for truck drivers
• Red Ribbon Express: Mobile awareness train for truckers and highway workers

F. Special Provisions for Truck Drivers (Bridge Population)

• Sentinel surveillance sites specifically for truckers (28 sites in 2016-17)
• TI (Targeted Intervention) projects at truck stops with peer educators
• Condom distribution at truck terminals
• Short-stay counselling during goods loading/unloading

IV. PMTCT (PREVENTION OF MOTHER-TO-CHILD TRANSMISSION) MEASURES

A. Antenatal Screening (Universal)

• Universal HIV and Syphilis testing integrated into routine ANC at all PHCs, CHCs, and secondary/tertiary facilities
• Opt-out testing approach: all pregnant women tested unless they refuse
• Testing done at ICTCs or PPTCT centres (linked to ART centres)

B. ART for HIV-Positive Pregnant Women

• All HIV-positive pregnant women are initiated on ART immediately (regardless of CD4 count or gestational age) under the Test and Treat policy
• Preferred regimen: TDF + 3TC + DTG (started as early as possible)
• Goal: Achieve and maintain undetectable viral load before delivery
• ART continued lifelong (not stopped post-delivery)
• If woman presents in labour and untested: Rapid test + ART immediately; ART stopped if test negative after confirmation at ICTC

C. Intrapartum Measures

• Institutional delivery is strongly encouraged
• Minimize invasive procedures: avoid artificial rupture of membranes, foetal scalp electrodes, episiotomy unless essential
• Elective Caesarean section at 38 weeks for women with viral load ≥1000 copies/mL (reduces intrapartum transmission risk)
• Universal precautions for all deliveries

D. ARV Prophylaxis for Infant

• Nevirapine (NVP) syrup given to the newborn within 6 hours of birth
• Duration of NVP prophylaxis depends on maternal viral load and breastfeeding status:
  • 6 weeks NVP if mother is on ART and virally suppressed
  • 12 weeks NVP if breastfeeding continues beyond 6 weeks
• Infant ART (3-drug regimen) if high-risk exposure

E. Infant Feeding Guidance

• Breastfeeding with ART: In resource-limited settings (India), WHO and NACP recommend exclusive breastfeeding for 6 months IF mother is on ART and virally suppressed, as the benefit of breastfeeding outweighs residual risk
• Mother counselled on proper breastfeeding technique and exclusive breastfeeding
• Replacement feeding (formula) advised only when it is AFASS (Acceptable, Feasible, Affordable, Sustainable, Safe)
• Avoid mixed feeding (increases mucosal HIV transmission risk)

F. Infant Diagnosis

• Early Infant Diagnosis (EID) using HIV DNA PCR (Dried Blood Spot):
  • First test at 6 weeks of age
  • Second test at 6 months
  • Third test at 12-18 months (if breastfeeding)
  • Antibody testing at 18 months for final serostatus determination
• HIV-positive infants immediately initiated on ART

G. Partner Services

• Husband/partner testing at ICTC
• ART for HIV-positive partners
• Partner counselling on condom use to prevent re-infection

H. Follow-up and Cascade

Summary Table